Morgan Lewis represented uniQure N.V. (Nasdaq: QURE), in connection with its underwritten public offering of 4.9 million ordinary shares at a public offering price of $46 per share, for gross proceeds of approximately $225 million. uniQure is a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs, with operations in Massachusetts and the Netherlands. The offering closed on September 10.
The Morgan Lewis team was led by partners Tim Corbett and Bryan Keighery, from our London and Boston offices, respectively, with assistance from associates Ben Stein, Max Kwon and Paul Lakkis.